Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Discovery and RIKEN GENESIS Sign Distribution Agreement

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
The agreement will see RIKEN GENESIS become sole distributor of Horizon’s molecular reference standards in Japan.

RIKEN GENESIS offers cutting-edge genomic products and services to a wide range of research institutions and corporations, and is a CAP (College of American Pathologists) accredited laboratory for genome analysis services. 

Reliable and renewable sources of reference standards are essential for molecular laboratories; however a lack of availability has previously been a major obstacle.  Even when patient samples are available, variability in DNA extraction and a lack of standardization have proven to be additional serious sources of error. Horizon’s HDx division has developed reliable and renewable genetically defined and thoroughly validated reference materials, providing an industry standard for the development of and quality control of molecular assays, thereby directly improving their accuracy.

Horizon’s Molecular Reference Standards include FFPE cell line blocks and purified gDNA. In early 2013 HDx launched its first Quantitative Multiplex DNA Reference Standard, intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).

“Part of our mission at RIKEN GENESIS is to contribute to translating the results of genetic research into clinical settings,” said Yusuke Tsukahara, President and CEO, RIKEN GENESIS. “Horizon’s Molecular Reference Standards are a valuable step in the move towards practical implementation of personalized medicine, and we are delighted to be working with such a forward looking company.” 

“At the cutting edge of genome analysis, RIKEN GENESIS is an ideal partner for Horizon. We aim to affiliate ourselves with the best, like-minded companies for distribution; those dedicated to customer service, cutting edge science and ultimately better patient care,” commented Dr Brian Burke, Business Development Manager, Horizon Diagnostics. “We look forward to working with the team to develop the molecular reference standards market in Japan.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Partners with EMQN
Horizon to provide genetically defined human genomic reference standards for cancer diagnostics proficiency testing schemes.
Tuesday, March 27, 2012
Horizon and UK NEQAS ICC Announce Partnership to Improve Accuracy of Lung Cancer Diagnostic Testing
Horizon’s genetically defined human genomic reference standards to be used in FISH and IHC proficiency testing to help guide personalised medicine.
Tuesday, January 31, 2012
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!